Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 198

1.

In vivo pharmacodynamics of lefamulin, the first systemic pleuromutilin for human use, in a neutropenic murine thigh infection model.

Wicha WW, Craig WA, Andes D.

J Antimicrob Chemother. 2019 Apr 1;74(Supplement_3):iii5-iii10. doi: 10.1093/jac/dkz085.

2.

In vivo pharmacokinetics and pharmacodynamics of the lantibiotic NAI-107 in a neutropenic murine thigh infection model.

Lepak AJ, Marchillo K, Craig WA, Andes DR.

Antimicrob Agents Chemother. 2015 Feb;59(2):1258-64. doi: 10.1128/AAC.04444-14. Epub 2014 Dec 15.

3.

Impact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the ceftolozane in vivo pharmacokinetic/pharmacodynamic target.

Lepak AJ, Reda A, Marchillo K, Van Hecker J, Craig WA, Andes D.

Antimicrob Agents Chemother. 2014 Oct;58(10):6311-4. doi: 10.1128/AAC.03572-14. Epub 2014 Aug 4.

4.

Editorial commentary: Are blood concentrations enough for establishing pharmacokinetic/pharmacodynamic relationships?

Craig WA.

Clin Infect Dis. 2014 Apr;58(8):1084-5. doi: 10.1093/cid/ciu055. Epub 2014 Jan 26. No abstract available.

PMID:
24470275
5.

Failure of clindamycin to eradicate infection with beta-hemolytic streptococci inducibly resistant to clindamycin in an animal model and in human infections.

Lewis JS 2nd, Lepak AJ, Thompson GR 3rd, Craig WA, Andes DR, Sabol-Dzintars KE, Jorgensen JH.

Antimicrob Agents Chemother. 2014;58(3):1327-31. doi: 10.1128/AAC.01877-13. Epub 2013 Dec 9.

6.

Exercise heart rate monitors for anxiety treatment in a rural primary care setting: a pilot study.

Houser MM, Rosen L, Seagrave MP, Grabowski D, Matthew JD, Craig WA.

Fam Med. 2013 Oct;45(9):615-21.

7.

Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam.

Dudley MN, Ambrose PG, Bhavnani SM, Craig WA, Ferraro MJ, Jones RN; Antimicrobial Susceptibility Testing Subcommittee of the Clinical and Laboratory Standards Institute.

Clin Infect Dis. 2013 May;56(9):1301-9. doi: 10.1093/cid/cit017. Epub 2013 Jan 18. Review.

PMID:
23334813
8.
10.

Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model.

Lepak AJ, Marchillo K, Pichereau S, Craig WA, Andes DR.

Antimicrob Agents Chemother. 2012 Nov;56(11):5916-22. doi: 10.1128/AAC.01303-12. Epub 2012 Sep 10.

11.

In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans.

Ambrose PG, Drusano GL, Craig WA.

Clin Infect Dis. 2012 Apr;54 Suppl 3:S220-8. doi: 10.1093/cid/cis001.

PMID:
22431852
12.

Forgotten antibiotics: an inventory in Europe, the United States, Canada, and Australia.

Pulcini C, Bush K, Craig WA, Frimodt-Møller N, Grayson ML, Mouton JW, Turnidge J, Harbarth S, Gyssens IC; ESCMID Study Group for Antibiotic Policies.

Clin Infect Dis. 2012 Jan 15;54(2):268-74. doi: 10.1093/cid/cir838. Review.

PMID:
22198992
13.

Fidaxomicin for Clostridium difficile Infection.

Safdar N, Craig WA.

N Engl J Med. 2011 May 12;364(19):1875; author reply 1875-6. doi: 10.1056/NEJMc1102685. No abstract available.

PMID:
21561360
14.

Protein binding: do we ever learn?

Zeitlinger MA, Derendorf H, Mouton JW, Cars O, Craig WA, Andes D, Theuretzbacher U.

Antimicrob Agents Chemother. 2011 Jul;55(7):3067-74. doi: 10.1128/AAC.01433-10. Epub 2011 May 2. Review.

15.

Optimizing aminoglycoside use.

Craig WA.

Crit Care Clin. 2011 Jan;27(1):107-21. doi: 10.1016/j.ccc.2010.11.006. Review.

PMID:
21144989
16.

In vivo pharmacodynamics of new lipopeptide MX-2401.

Craig WA, Andes DR, Stamstad T.

Antimicrob Agents Chemother. 2010 Dec;54(12):5092-8. doi: 10.1128/AAC.00238-10. Epub 2010 Sep 20.

17.
18.

Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists.

Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M, Dalovisio JR, Levine DP.

Clin Infect Dis. 2009 Aug 1;49(3):325-7. doi: 10.1086/600877. Erratum in: Clin Infect Dis. 2009 Nov 1;49(9):1465.

PMID:
19569969
19.

In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models.

Craig WA, Andes DR.

Antimicrob Agents Chemother. 2008 Oct;52(10):3492-6. doi: 10.1128/AAC.01273-07. Epub 2008 Aug 1.

21.

Tissue concentrations: do we ever learn?

Mouton JW, Theuretzbacher U, Craig WA, Tulkens PM, Derendorf H, Cars O.

J Antimicrob Chemother. 2008 Feb;61(2):235-7. Epub 2007 Dec 6. Review.

PMID:
18065413
22.

Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model.

Ambrose PG, Forrest A, Craig WA, Rubino CM, Bhavnani SM, Drusano GL, Heine HS.

Antimicrob Agents Chemother. 2007 Dec;51(12):4351-5. Epub 2007 Sep 17.

23.

In vivo pharmacodynamic activity of the glycopeptide dalbavancin.

Andes D, Craig WA.

Antimicrob Agents Chemother. 2007 May;51(5):1633-42. Epub 2007 Feb 16.

24.

Tigecycline: a critical analysis.

Stein GE, Craig WA.

Clin Infect Dis. 2006 Aug 15;43(4):518-24. Epub 2006 Jun 26. Review.

PMID:
16838243
25.

Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target.

Andes D, Craig WA.

Antimicrob Agents Chemother. 2006 Apr;50(4):1376-83. Erratum in: Antimicrob Agents Chemother. 2014 Apr;58(4):2489. Dosage error in article text.

26.

Outcomes evaluation of patients with ESBL- and non-ESBL-producing Escherichia coli and Klebsiella species as defined by CLSI reference methods: report from the SENTRY Antimicrobial Surveillance Program.

Bhavnani SM, Ambrose PG, Craig WA, Dudley MN, Jones RN; SENTRY Antimicrobial Surveillance Program.

Diagn Microbiol Infect Dis. 2006 Mar;54(3):231-6. Epub 2006 Jan 19.

PMID:
16423491
27.

Pharmacodynamics of a new streptogramin, XRP 2868, in murine thigh and lung infection models.

Andes D, Craig WA.

Antimicrob Agents Chemother. 2006 Jan;50(1):243-9.

28.

Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations.

Andes D, Craig WA.

Clin Microbiol Infect. 2005 Nov;11 Suppl 6:10-7. Review.

29.
30.

Inhibition of mutation and combating the evolution of antibiotic resistance.

Cirz RT, Chin JK, Andes DR, de Crécy-Lagard V, Craig WA, Romesberg FE.

PLoS Biol. 2005 Jun;3(6):e176. Epub 2005 May 10.

31.

The inoculum effect: fact or artifact?

Craig WA, Bhavnani SM, Ambrose PG.

Diagn Microbiol Infect Dis. 2004 Dec;50(4):229-30. No abstract available.

PMID:
15582294
32.

Future trends in antimicrobial chemotherapy: expert opinion on the 43rd ICAAC.

Ball AP, Bartlett JG, Craig WA, Drusano GL, Felmingham D, Garau JA, Klugman KP, Low DE, Mandell LA, Rubinstein E, Tillotson GS.

J Chemother. 2004 Oct;16(5):419-36. Review.

PMID:
15565907
33.

The importance of bactericidal drugs: future directions in infectious disease.

Finberg RW, Moellering RC, Tally FP, Craig WA, Pankey GA, Dellinger EP, West MA, Joshi M, Linden PK, Rolston KV, Rotschafer JC, Rybak MJ.

Clin Infect Dis. 2004 Nov 1;39(9):1314-20. Epub 2004 Oct 7. Review.

PMID:
15494908
34.

Overview of newer antimicrobial formulations for overcoming pneumococcal resistance.

Craig WA.

Am J Med. 2004 Aug 2;117 Suppl 3A:16S-22S. Review.

PMID:
15360093
35.

Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections.

Andes D, Anon J, Jacobs MR, Craig WA.

Clin Lab Med. 2004 Jun;24(2):477-502. Review.

PMID:
15177850
36.

Proof of concept: performance testing in models.

Craig WA.

Clin Microbiol Infect. 2004 Apr;10 Suppl 2:12-7. Review.

37.

Antimicrobial treatment guidelines for acute bacterial rhinosinusitis.

Anon JB, Jacobs MR, Poole MD, Ambrose PG, Benninger MS, Hadley JA, Craig WA; Sinus And Allergy Health Partnership.

Otolaryngol Head Neck Surg. 2004 Jan;130(1 Suppl):1-45. Review. No abstract available. Erratum in: Otolaryngol Head Neck Surg. 2004 Jun;130(6):794-6.

PMID:
14726904
38.
39.

In vivo pharmacodynamic activity of daptomycin.

Safdar N, Andes D, Craig WA.

Antimicrob Agents Chemother. 2004 Jan;48(1):63-8.

40.

Pharmacodynamics of the new des-f(6)-quinolone garenoxacin in a murine thigh infection model.

Andes D, Craig WA.

Antimicrob Agents Chemother. 2003 Dec;47(12):3935-41.

41.
42.

mecA-blaZ corepressors in clinical Staphylococcus aureus isolates.

Rosato AE, Kreiswirth BN, Craig WA, Eisner W, Climo MW, Archer GL.

Antimicrob Agents Chemother. 2003 Apr;47(4):1460-3.

44.

In vivo pharmacodynamics of a new oxazolidinone (linezolid).

Andes D, van Ogtrop ML, Peng J, Craig WA.

Antimicrob Agents Chemother. 2002 Nov;46(11):3484-9.

45.
46.

Animal model pharmacokinetics and pharmacodynamics: a critical review.

Andes D, Craig WA.

Int J Antimicrob Agents. 2002 Apr;19(4):261-8. Review.

PMID:
11978497
48.

Does the dose matter?

Craig WA.

Clin Infect Dis. 2001 Sep 15;33 Suppl 3:S233-7. Review.

PMID:
11524724
49.

Pharmacokinetics of antibiotics with special emphasis on cephalosporins.

Craig WA.

Clin Microbiol Infect. 2000;6 Suppl 3:46-9. Review. No abstract available.

50.

Supplemental Content

Loading ...
Support Center